SCHEMBL9284

SCHEMBL9284

O=S(=O)(Cl)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.59
KMT2A Q03164 1/20 0.50
TAAR1 Q96RJ0 1/20 0.45
IDO1 P14902 2/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
CHRM5 P08912 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 1/20 0.41
DAO P14920 2/20 0.40
MAOB P27338 1/20 0.40
CYP19A1 P11511 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066135 0.91 KIF11 (0.75) KIF11KMT2ATAAR1IDO1BCHE
SCHEMBL7243419 0.82 CA2 (0.40) KIF11KMT2AKDM4EALDH1A1CA1
SCHEMBL16140113 0.81 KIF11 (0.61) KIF11KMT2ATAAR1IDO1BCHE
SCHEMBL27741752 0.80 TAAR1 (0.52) KIF11KMT2ATAAR1IDO1KDM4E
SCHEMBL773148 0.79 IDO1 (0.44) KIF11KMT2AIDO1DAO
SCHEMBL2375555 0.79 KIF11 (0.59) KIF11KMT2ATAAR1IDO1BCHE
SCHEMBL16914823 0.79 ALDH1A1 (0.45) KMT2AALDH1A1BCHEACHECA1
SCHEMBL3130035 0.79 KIF11 (0.89) KIF11KMT2ATAAR1IDO1BCHE
SCHEMBL496716 0.79 KIF11 (0.59) KIF11KMT2ATAAR1IDO1BCHE
SCHEMBL2375558 0.79 KIF11 (0.59) KIF11KMT2ATAAR1IDO1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113461880-A Polylactic acid injection molding method 无锡御束生物材料科技有限公司 2021-10-01 CN claimed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 EP disclosed
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2026-03-10 US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 EP disclosed
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY INST NAT SANTE RECH MED (FR) 2025-11-20 US disclosed
WO-2025120168-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2025-06-12 WO disclosed
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 EP disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 US disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 WO disclosed
US-6080871-A ANTIHISTAMINES JAMES BLACK FOUNDATION LIMITED (GB) 2000-06-27 US disclosed
EP-0835109-A4 PYRIDINONE-THROMBIN INHIBITORS MERCK & CO INC (US) 1999-02-03 EP disclosed
EP-0882023-A1 HISTAMINE H 3 RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 1998-12-09 EP disclosed
US-5744486-A Pyridinone thrombin inhibitors MERCK & CO., INC. (US) 1998-04-28 US disclosed
EP-0835109-A1 PYRIDINONE-THROMBIN INHIBITORS Merck & Co., Inc. (US) 1998-04-15 EP disclosed
US-5668289-A Pyridinone thrombin inhibitors MERCK & CO., INC. (US) 1997-09-16 US disclosed
WO-1997029092-A1 HISTAMINE H3 RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 1997-08-14 WO disclosed
WO-1997001338-A1 PYRIDINONE-THROMBIN INHIBITORS MERCK & CO., INC. (US) 1997-01-16 WO disclosed
WO-1994018165-A1 SULFONAMIDE COMPOUNDS AS OPIOID K-RECEPTOR AGONISTS PFIZER INC. (US) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 KIF11 4178/4885KMT2A 4320/4885TAAR1 2815/4885
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer CKS2, CSNK2A3, CSNK1A1L KIF11 1479/4885KMT2A 1423/4885TAAR1 685/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 KIF11 2559/4885KMT2A 3281/4885TAAR1 1973/4885
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY TALDO1, TBCA, TBCD KIF11 3000/4885KMT2A 3848/4885TAAR1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.